In the revised criteria for the diagnosis and staging of AD, positron emission tomography (PET) imaging of amyloid beta (Aβ) and neurofibrillary tangle tau pathologies are considered the essential biomarkers of AD neuropathologic changes (i.e., Core 1 biomarkers).8 The gene discussed is MAPT; the disease is Alzheimer disease.